Authors
Dylan A Marshall, Karen A Litwa, Ken Soderstrom
Published in
Frontiers in pharmacology. Volume 17. Pages 1972787. Epub Oct 09, 2026.
Abstract
Chronic neuroinflammation following traumatic brain injury (TBI) increases the risk of affective disorders and early-onset dementias. Existing anti-inflammatory therapies are limited by systemic side effects with chronic use and by poor brain penetration of newer biologics. Cannabidiol (CBD), a non-euphorigenic phytocannabinoid with a favorable safety profile and multi-target neuroprotective actions, is a promising alternative. Using a songbird microlesion model of learned vocal recovery after targeted damage to the premotor nucleus HVC, we previously showed that systemic CBD (10 mg/kg/day) reduces vocal disruption, inflammatory cytokines, oxidative stress, and synaptic loss. Here we tested the hypothesis that these benefits involve astrocytes. CBD (10 mg/kg/day IM for 7 days) preserved astrocyte viability, attenuated injury-induced lysosomal stress, suppressed reactivity markers (C3, S100A10, aromatase), and upregulated key metabolic and antioxidant transcripts (glutamine synthetase and GCLM) across the interconnected song-control nuclei HVC, RA, and Area X. These changes were accompanied by reduced neuronal apoptosis in lesioned HVC. The results identify astrocyte-associated responses as a candidate cellular substrate of CBD's circuit-wide protective effects and support its translational potential to mitigate secondary injury and communication deficits after TBI.
PMID:
42920500
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0